Earnings ·
Purple Biotech reports $0.4M net income on warrant gain, holds $6.1M cash runway through mid-2027
PPBTPurple Biotech Ltd.
Purple Biotech Ltd. reported second quarter 2026 financial results on August 7, 2026. The company held $6.1 million in cash as of June 30, 2026, providing a runway through mid-2027. R&D expenses rose to $0.7 million from $0.6 million year-over-year, while G&A decreased to $0.6 million from $0.7 million. Operating loss was $1.3 million compared to $1.2 million in the prior period. Net income turned positive at $0.4 million due to a non-cash gain from warrant revaluation, contrasting with a net loss of $1.1 million previously. The company presented new preclinical data for IM1240 at EACR 2026 and plans to enter clinical studies in 2027. Purple Biotech Ltd. is a clinical-stage biotechnology company developing next-generation immunotherapy platforms.